{"id":"ac-170-vehicle","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vehicle formulation, AC-170 Vehicle serves as the delivery system for the active drug AC-170, optimizing bioavailability and residence time in the eye. The specific mechanism of AC-170 itself is not publicly detailed, but the vehicle formulation is engineered to enhance ocular penetration and therapeutic efficacy for ophthalmologic conditions.","oneSentence":"AC-170 Vehicle is a formulation component designed to deliver the active pharmaceutical ingredient AC-170 to ocular tissues.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:48.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ocular hypertension or glaucoma (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT01881113","phase":"PHASE3","title":"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2013-06","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01551056","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-03","conditions":"Allergic Conjunctivitis","enrollment":91},{"nctId":"NCT01685242","phase":"PHASE3","title":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-09","conditions":"Allergic Conjunctivitis","enrollment":100},{"nctId":"NCT01134328","phase":"PHASE2","title":"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":83},{"nctId":"NCT02756624","phase":"PHASE3","title":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":516},{"nctId":"NCT02132169","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-05","conditions":"Atopic Disease (Including Allergic Conjunctivitis)","enrollment":512},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AC-170 Vehicle","genericName":"AC-170 Vehicle","companyName":"Nicox Ophthalmics, Inc.","companyId":"nicox-ophthalmics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-170 is a vehicle used in clinical trials for the treatment of allergic conditions such as Allergic Conjunctivitis, Atopic Disease, Rhinitis, and other allergic conditions. It has been tested in concentrations of 0.05%, 0.1%, and 0.24% in studies evaluating its efficacy in treating these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}